Oragenics Inc. Files 8-K Report
Ticker: OGEN · Form: 8-K · Filed: Oct 18, 2024 · CIK: 1174940
Sentiment: neutral
Topics: disclosure, regulatory-filing
TL;DR
Oragenics filed an 8-K, likely standard disclosures. No major news yet.
AI Summary
On October 18, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the submission of Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Oragenics, Inc. is complying with regulatory requirements for reporting material information and financial updates to the SEC.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate material adverse events.
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- October 18, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for Oragenics, Inc.?
The filing is primarily for Regulation FD Disclosure and to submit Financial Statements and Exhibits.
What is Oragenics, Inc.'s principal executive office address?
The address is 1990 Main Street, Suite 750, Sarasota, FL 34236.
What is Oragenics, Inc.'s telephone number?
The telephone number is 813-286-7900.
What is Oragenics, Inc.'s state of incorporation?
Oragenics, Inc. is incorporated in Florida (FL).
What is the SIC code for Oragenics, Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-10-18 08:30:10
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 7KB
- 0001493152-24-041500.txt ( ) — 220KB
- ogen-20241018.xsd (EX-101.SCH) — 3KB
- ogen-20241018_lab.xml (EX-101.LAB) — 33KB
- ogen-20241018_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this October 18, 2024. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Financial Officer